Abstract
Introduction: In August 2017, the United States Federal Drug Administration (FDA) approved enasidenib (Idhifa, Celgene/Agios) for adults with relapsed......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
